Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech’s lead product candidate – satraplatin – is an oral platinum-based compound that has shown highly statistically significant results for progression-free survival in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and the rolling NDA submission process for this compound is underway. Satraplatin was in-licensed from Spectrum Pharmaceuticals, ( www.gpc-biotech.com )
GPC Biotech AG
610 Lincoln Street
Waltham, Massachusetts 02451
USA
Tel: (781) 890-9007
Fax: (781) 890-9005